Highlights The pathophysiology of SARS-CoV-2 infection may be attributed to cytokine release syndrome. In this syndrome, interleukin 6 is released after the activation of the inflammatory cascade. The mortality rate in the current study was 16%. Tocilizumab may be a promising agent to decrease the mortality rate in severe or critical SARS-CoV-2 infection.

FCLB method provides larger tissue samples with better quality compared with TBLB. Higher-quality specimens are associated with less artifact and higher diagnostic yield. Multisite randomized trials are required to improve our knowledge about the benefits and indications of TBLB with cryoprobe.

Background Since the outbreak of the novel coronavirus disease-2019 (COVID-19) in December 2019, limited studies have investigated the histopathologic findings of patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Material and methods This study was conducted on 31 deceased patients who were hospitalized for COVID-19 in a tertiary hospital in Tehran, Iran. A total of 52 postmortem tissue biopsy samples were obtained from the lungs and liver of decedents. Clinical characteristics, laboratory data, and microscopic features were evaluated. Reverse transcription polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 was performed on specimens obtained from nasopharyngeal swabs and tissue biopsies. Results The median age of deceased patients was 66 years (range, 30–87 years) and 25 decedents (81 %) were male. The average interval from symptom onset to death was 13 days (range, 6–34 days). On histopathologic examination of the lung specimens, diffuse alveolar damage and thrombotic microangiopathy were the most common findings (80 % and 60 %, respectively). Liver specimens mainly showed macrovesicular steatosis, portal lymphoplasmacytic inflammation and passive congestion. No definitive viral inclusions were observed in any of the specimens. In addition, 92 % of lung tissue samples tested positive for SARS-CoV-2 by RT-PCR. Conclusions Further studies are needed to investigate whether SARS-CoV-2 causes direct cytopathic changes in various organs of the human body.